Clinical Trial

Title: A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)

MOA: IINCA033989 inhibits mutCALR induced JAK/STAT signaling and oncogenic cell proliferation.

Key Eligibility

• Confirmed diagnosis of high-risk ET
• Presence of a pathogenic CALR exon 9 mutation
  based on central lab results
• Prior treatment with at least 1 cytoreductive therapy,
  with inadequate or loss of response to the most recent
  prior ET therapy or intolerance/unacceptable toxicity
• ECOG 0-2
• Excludes presence of hematologic malignancy other
  than ET
• Prior allogenic or autologous stem-cell transplantation
  not allowed